Walleye Capital LLC Sells 37,827 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Walleye Capital LLC reduced its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 39.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,434 shares of the company’s stock after selling 37,827 shares during the quarter. Walleye Capital LLC’s holdings in NewAmsterdam Pharma were worth $1,870,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of NAMS. Farther Finance Advisors LLC raised its holdings in shares of NewAmsterdam Pharma by 4,425.0% during the 4th quarter. Farther Finance Advisors LLC now owns 724 shares of the company’s stock valued at $25,000 after buying an additional 708 shares in the last quarter. Wells Fargo & Company MN lifted its position in NewAmsterdam Pharma by 50.0% in the 4th quarter. Wells Fargo & Company MN now owns 900 shares of the company’s stock worth $32,000 after buying an additional 300 shares during the last quarter. KBC Group NV purchased a new stake in NewAmsterdam Pharma in the first quarter worth approximately $37,000. Navalign LLC purchased a new stake in NewAmsterdam Pharma in the fourth quarter worth approximately $46,000. Finally, Empowered Funds LLC bought a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $85,000. 89.89% of the stock is currently owned by institutional investors.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 65,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $35.69, for a total value of $2,319,850.00. Following the completion of the transaction, the chief accounting officer directly owned 24,353 shares of the company’s stock, valued at $869,158.57. This represents a 72.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.74% of the stock is currently owned by insiders.

NewAmsterdam Pharma Trading Down 3.6%

Shares of NewAmsterdam Pharma stock opened at $30.55 on Friday. NewAmsterdam Pharma Company N.V. has a 12-month low of $21.14 and a 12-month high of $42.21. The company has a market cap of $3.57 billion, a P/E ratio of -17.07 and a beta of 0.08. The company’s fifty day simple moving average is $32.92 and its two-hundred day simple moving average is $32.89.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. The company had revenue of $3.04 million during the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%. Analysts predict that NewAmsterdam Pharma Company N.V. will post -1.78 EPS for the current fiscal year.

Analysts Set New Price Targets

NAMS has been the topic of several research reports. Royal Bank Of Canada lifted their price target on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a research note on Monday. They issued an “outperform” rating and a $58.00 price objective for the company. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Jefferies Financial Group reissued a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $49.42.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.